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S U M M A R Y
Background: The importance of the C-C chemokine receptor type 5 (CCR5) in HIV infection and disease
progression was recognized with the discovery of the D32 allele. Individuals homozygous for this
mutation lack functional CCR5, and are almost completely resistant to HIV infection. Heterozygous
individuals display decreased cell surface CCR5, which slows disease progression. Phenotypic expression
of CCR5 is heterogeneous and its relation to genetic mutations in the CCR5 gene is not currently known
for the South African population. This provided the rationale for investigating genetic variation in low
CCR5 expressers in South Africa.
Methods: Flow cytometry was used to measure the phenotypic distribution of CCR5 in 245 individuals
by assessing both the percentage of CD4 + CCR5+ T-cells and CCR5 density.
Results: Genotypic data revealed 70 single nucleotide polymorphisms (SNPs), four insertions, and the
D32 deletion within the 65 individuals selected for sequencing. The D32 mutation was detected only in
the Caucasian group and included a single homozygous individual with an absence of CCR5 expression. A
total of eight previously described open reading frame (ORF) mutations were found in this study, as well
as 12 novel mutations with two in the ORF. Greater genetic diversity was present in the black South
African group, with 39 mutations being exclusive to this group.
Conclusions: Using a unique approach to genotype in individuals with lower CCR5 expression we have
identiﬁed novel SNPs which could affect HIV infection.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Although the devastating effect of HIV is manifested globally,
the magnitude of the infection is most prominent in Sub-Saharan
Africa. Despite consistent attempts to develop an effective vaccine
against the virus, reliance on relatively toxic antiretrovirals (ARVs)
is still the best choice of treatment.
HIV gains entry into host cells via its glycoprotein 120 receptor
(gp120), which binds to host cell receptor cluster differentiation
four (CD4+) on T-lymphocytes.1 In order for the virus to enter the
host cell it requires membrane fusion. This occurs via the virus’
glycoprotein 41 receptor (gp41), which catalyzes the fusion of the
virus to a host co-receptor, being either C-C chemokine receptor
type 5 (CCR5) or chemokine receptor type four (CXCR4), and
anchors the virus to the host membrane. The CCR5 co-receptor is
crucial for HIV infection, as demonstrated by the discovery of the
CCR5 delta 32 (D32) allele.2 The D32 mutation contains a 32-base
pair (bp) deletion in the open reading frame (ORF) of the CCR5* Corresponding author. Tel.: +27 (0)12 420 5317; fax: +27 (0)12 420 3953.
E-mail address: michael.pepper@up.ac.za (M.S. Pepper).
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and retards disease progression in heterozygotes. The mutated
protein is unable to insert into the host cell membrane,2 which
renders the cell resistant to HIV, as the virus cannot fuse with the
host cell surface and is thereby denied entry into the cell.
The importance of D32 was highlighted following a study
conducted in 2009 by Hu¨tter et al.3 The study demonstrated that
performing a stem cell transplant on an HIV-positive individual,
using a histocompatibility leukocyte antigen-matched (HLA) HIV-
negative donor homozygous for the D32 mutation, rendered the
HIV-positive individual free of viral detection 20 months post-
transplantation. An update in 2011 by the group conﬁrmed that the
HIV-infected patient remains free of viral replication and his
immune system has been reconstituted with that of the D32
homozygous donor.4 The group suggests that the individual is
‘cured’ of HIV.
The D32 mutation is most common in individuals of European
descent, but is absent or rare in the black African population.5
Other mutations have, however, been identiﬁed in African
populations, such as the C101X mutation,6 which is known to
provide resistance to HIV.7 Several novel mutations have also been
identiﬁed in small cohorts in South Africa.8 These include the D2 Vses. Published by Elsevier Ltd. All rights reserved.
F. Barmania et al. / International Journal of Infectious Diseases 17 (2013) e1148–e1153 e1149mutation with decreased binding to HIV, and the R225X
mutation, which like the D32 mutation, results in the absence
of receptor expression and no interaction of the receptor with
HIV in vitro.9
In South Africa, studies have been conducted to describe
previously identiﬁed mutations,10 as well as novel mutations in
the population.8 While studies have been performed to evaluate
the in vitro effect of novel South African mutations on HIV,9,11
there are currently no studies describing CCR5 expression
levels in the population groups and how these levels are
inﬂuenced by genetic variability in CCR5. The above studies have
also focused on discovering mutations in exon 3 of the CCR5
gene, which houses the ORF. In 2010, Picton et al. analyzed the
entire 9.2-kb region of CCR5 in 35 black and Caucasian South
Africans for single nucleotide polymorphisms (SNPs), indels
(insertions and deletions), and haplotypes.12 In the small cohort
of individuals studied, 68 SNPs, ﬁve indels, and seven haplotypes
were found. Research into the effects of these mutants on CCR5
expression, HIV infection, and disease progression has not been
reported.
Considering that reduced CCR5 expression has been associated
with delayed HIV progression, this study used a novel approach to
determine the genotypic variation within the CCR5 gene in the
South African population. By targeting individuals with phenotyp-
ically low CCR5 expression using ﬂow cytometry methods, theTable 1
Flow cytometry data of 65 individuals genotyped
CCR5 MFI range Black African 
Sample ID MFI CD4+ T-cell % CD4+CC
0–3.5 F051 1.4 50.5 12.3 
F039 1.6 7.6 25.9 
F037 1.8 11.1 11.3 
F047 2.1 14.4 31 
F048 2.3 15.2 17.3 
F114 2.5 51.5 34.5 
F158 2.7 49 26.8 
F142 2.7 27 29.2 
F099 2.8 11.6 9.9 
F172 2.8 48.7 5.8 
F086 2.9 28.3 55.9 
F059 3.1 13.2 13.9 
F135 3.1 39.6 10.6 
F009 3.2 26 17.9 
F216 3.3 47.9 7.8 
F084 3.3 34.6 20 
F173 3.3 38.8 8.6 
F081 3.4 45.8 26.9 
F184 3.4 28.9 25.6 
3.6–6 F115 3.7 8.8 13.5 
F203 4.1 30.6 4.8 
F102 4.1 36.5 12.6 
F007 5.0 46 17.3 
F119 5.0 32.4 42.6 
F021 5.0 22.7 32.1 
F101 5.9 53.5 9.4 
F068 6.0 40.2 9.5 
F200 6.0 60.4 6.1
F228 6.0 51.4 8.1
>6 
F032b 5.2 26.5
MFI, mean ﬂuorescence intensity.
a Individuals found with the D32 mutation.
b F032 indicates the individual of Indian descent; the ﬂow data fall within the commstudy aimed to discover novel mutations in the CCR5 gene that
could explain the phenotype.
2. Materials and methods
The study was approved by the University of Pretoria Health
Sciences Research Ethics Committee, and informed consent was
obtained from all individuals.
2.1. Study population
Peripheral blood was drawn at the Steve Biko Academic
Hospital by trained personnel. The samples were processed
within 6 h of collection. Flow cytometry analysis of CCR5
expression was performed on a cohort of 245 randomly selected
South African individuals, of whom 124 were black and 110
Caucasian. Eleven individuals formed part of the colored and
Indian population groups. There were no speciﬁc selection
criteria.
A total of 65 individuals, identiﬁed based on their low
expression levels of CCR5 by ﬂow cytometry, were genotyped
(Table 1). The population genotyped included 29 black, 35
Caucasian, and one Indian individual. Forty-ﬁve of the individuals
sequenced were identiﬁed within the lower range of CCR5 density
(0–3.5), 19 individuals were within the normal range of CCR5Caucasian
R5+ % Sample ID MFI CD4+ T-cell % CD4+CCR5+ %
F092a 0.0 29.4 0
F054a 1.3 8.7 10.4
F042a 1.4 4.9 10.7
F044 1.6 9.5 14.1
F043 1.6 20.6 5.4
F050 1.7 18.9 10.7
F040 1.7 10.1 18.4
F052 1.8 4.7 35.6
F055 1.8 11.7 12.8
F046 1.8 15 14.6
F049 1.8 7.6 20.4
F056 1.8 4.9 18.6
F053 1.9 13 8.4
F045 1.9 12.9 18.5
F087a 2.4 26.5 16.8
T001a 2.5 36.2 6.9
F157a 2.7 35.6 6.6
F024a 2.8 27.2 9.7
F014 2.9 50.1 8.35
F002a 2.9 39.7 11.7
F033a 3.0 47 12.3
F029 3.1 40.2 6.8
F030 3.1 41.4 19.9
F154a 3.1 37 15.8
F104a 3.1 36.4 16.7
F103 3.2 42.8 6.7
F070 3.7 36.3 12.1
F197a 3.8 48.2 8.3
F105 4.1 53.3 9.6
F195 4.2 59.3 9.5
F093 4.7 39.2 23.4
F121 5.1 24.3 41.5
F062 5.3 57.4 8.9
T002 5.5 34.8 17.2
F010 7.2 22.8
only found range in the present study (3.6–6).
Figure 1. Distribution of CCR5 density. Histogram illustrating the distribution of
CCR5 density (mean ﬂuorescence intensity, MFI) in 245 South African individuals as
assessed by ﬂow cytometry. MFI in most individuals was between 3.6 and 6
arbitrary units. All individuals with low CCR5 density (n = 45) were genotyped. The
remaining individuals genotyped (n = 20) were randomly selected from the 3.6–6
and >6 regions. The MFI was used as a qualitative measure of density.
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arbitrary units (Figure 1).
2.2. Whole blood cell surface staining and CCR5 phenotypic analysis
Whole blood (50 ml) was incubated with 10 ml each of CD4-
FITC (Beckman Coulter, Miami, FL, USA) and CCR5-PE (BioLegend,
San Diego, CA, USA) monoclonal antibodies for 20 min. Erythro-
cytes were lysed with VersaLyse lysing solution (Beckman Coulter)
and ﬂow cytometry analysis was performed on a Beckman Coulter
Cytomics FC500 ﬂow cytometer. The expression of CCR5 on CD4+ T-
cells was analyzed after selecting the lymphocyte region using
forward and side scatter and then gating for CD4+ cells. The CXP
system software was used to calculate the percentage of CD4+CCR5+
T-cells and the mean ﬂuorescence intensity (MFI), which indicated
qualitative CCR5 density (Figure 1), for each sample.
2.3. PCR and sequencing of CCR5
The Maxwell 16 Blood DNA Puriﬁcation Kit (Promega, Madison,
WI, USA) was used to extract genomic DNA. A 9028-bp region of
the CCR5 gene was ampliﬁed using four primer pairs (see
Supplementary Material) (GenBank: U95626). The fragment
ampliﬁed included the entire coding region as well as ﬂanking
regions of the CCR5 gene. Sequencing was performed using an ABI
version 3.1 BigDye Kit and ABI3500xl Genetic Analyzer. Primers
were designed using the CLC Bio Genomic Workbench software
program. Sequencing data were assembled and aligned with the
reference sequence (GenBank: U95626) using the CLC Bio Genomic
Workbench software program and analyzed for the presence of
SNPs, insertions, and deletions. The CCR5 gene was numbered by
delineating the ﬁrst nucleotide of the start of translation as +1 and
the nucleotide immediately upstream as 1 (CCR5 AIDS Sympo-
sium held at the NCI-FCRDC, Frederick, MD, USA, April 30, 1999).
Mutations detected in this study were compared with the GenBank
dbSNP database and other published literature to identify novel
mutations.
2.4. Characterization of D32 deletion mutant
Cloning was performed using the CloneJET PCR Cloning Kit
(Fermentas Life Sciences, Inc., MD, USA), and Z-Competent E. Coli
Cells (Zymo Research Corp., Irvine, CA, USA) were used for
transformation. Sequencing was used to determine the putative
deletion by screening for the allele within the recombinant
plasmids. Sequencing products were aligned with the reference
sequence to characterize the deletion.3. Results
3.1. 50 Flanking region
In the 50 ﬂanking region of the CCR5 gene, 17 mutations were
found, which included one novel mutation (Table 2). Two of the
mutations detected have previously been identiﬁed in South Africa
as being novel.12 The mutations in this region consisted of 15 SNPs
and two insertions. The insertion at position 3879 was found as a
combination of two previously described polymorphisms: acces-
sion number rs145381188 reporting a CTAT insertion, and
accession number rs41412948 reporting a C/T SNP at the same
location. The mutation was found in two Caucasian individuals.
Seven of the mutations found were exclusive to the black South
African population, while three were exclusive to the Caucasian
group and included the novel C/T SNP at position 5420.
3.2. Introns
In intron 1, ﬁve SNPs were identiﬁed, of which two were
previously identiﬁed as being novel in the South African
population,12 while one was newly identiﬁed in this study
(Table 2). The novel A/G SNP identiﬁed in this study was found
at position 2273 in two black South African heterozygous
individuals. All ﬁve SNPs identiﬁed were found in the black South
African group, with only the SNPs at positions 2549 and 2454
being found in the Caucasian group.
Eighteen mutations were detected in the second intron,
consisting of 16 SNPs and two insertions. The C/T SNP at position
1188 has been identiﬁed previously in the South African
population,12 while four novel SNPs were identiﬁed in this study.
These included SNPs at position 1498, 783, 508, and 10. The
C/T SNP at position 1498 was found in both the black and
Caucasian South African groups, while the G/A SNP at position
783 and the C/G SNP at position 10 were found only in the black
African group. The G/A SNP at position 508 was found in a single
heterozygous Caucasian individual.
3.3. Exons
A single A/G SNP was detected at position 2728 of exon 1 at a
lower frequency in black individuals than in Caucasian South
Africans (Table 2).
In exon 2a, four SNPs were detected at positions 2130, 2127,
2081, and 2043 (Table 2). The SNPs at positions 2130 and
2081 were found at high frequencies in both the black and
Caucasian South African groups. The C/T SNP at position 2127 and
the C/G SNP at position 2043 were only found in the black South
African group. There were no mutations detected in exon 2b.
3.4. ORF
Eleven mutations were detected including the D32 deletion and
two novel SNPs (Table 3). The D32 deletion was found in 12
Caucasian individuals and was not detected in the black South
African group. The novel C/T SNP at position 667 was found in both
population groups, while the A/C SNP at position 817 was only
found in the black South African group. Two mutations that have
been identiﬁed previously in the South African population were
also identiﬁed in this study.8
3.5. 30 Flanking region
Nineteen SNPs were detected in the 30 ﬂanking region, with four
novel mutations being identiﬁed in this study (Table 2). Five
mutations have been identiﬁed previously in the South African
Table 2
Mutations detected in black African and Caucasian South African individuals
Gene region Position Base
change
wt/ma
Accession
number/
referenceb
50 Flanking region
(2715 bp)
5272c G/A rs3136535
5270 G/A rs6776227
5240 C/T N
5218 T/C 12
5084 T/A rs41429449
4749 C/T rs3136536
4349c A/G rs7637813
4248c A/C rs41490645
4079 T/A rs41499550
3891c C/A rs72622924/
rs2856757
3886 T/C rs41395049
3879 -/C/TTAT rs145381188/
rs41412948
3875c -/CTAT rs10577983
3827 C/T 12
3453c G/T rs2734225
3256 G/A rs41475349
2847c A/G rs2227010
Exon 1
(57 bp)
2728c A/G rs2856758
Intron 1
(501 bp)
2572 T/G 12
2549c T/G rs2734648
2454c G/A rs1799987
2449 G/A 12
2273 A/G N
Exon 2a
(235 bp)
2130c T/C rs1799988
2127 C/T rs41469351
2081c G/A rs1800023
2043 C/G rs41355345
Intron 2
(1909 bp)
1830 C/T rs1800024
1681 A/C rs9282632
1498 C/T N
1459 A/G rs3181037
1188 C/T 12
1126c GA/- rs3054375
1057 C/T rs2856762
973c C/T rs2254089
972 G/A rs41395249
783 G/A N
648c C/T rs2856764
508 G/A N
441c A/G rs2856765/
rs35046662
359c G/A rs41515644
353 CAA/- 20
113 G/T rs3176763
112 G/A rs41352147
10 C/G N
30 Flanking region
(2498 bp)
1134 G/A N
1197 C/A N
1253 A/G 12
1349 A/G N
1477 C/T N
1752 G/A rs41495153
1823 C/T rs17765882
1843 G/A rs41418945
1846 G/A rs41466044
2066 G/A 12
2077c T/G rs1800874
2225 T/C rs41535253
2381 A/G 12
2435 T/A 12
2458 A/C rs3188094
2676 C/A rs41442546
2838 C/G rs41512547
2919c T/G rs746492
Table 2 (Continued )
Gene region Position Base
change
wt/ma
Accession
number/
referenceb
3132 T/G 12
a For base change, ‘wt’ refers to wild-type allele and ‘m’ refers to mutant allele.
b Accession numbers as found in the SNP database (dbSNP), or reference number
for the study in which the mutation was discovered. N refers to novel mutation
detected in this study.
c Mutations found in a single Indian individual. The insertion at position 3879 is
a combination of two reference sequences.
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+1349, and +1377 were found exclusively in the black South
African population, while the SNP at position +1134 was found in a
Caucasian individual.
4. Discussion
Cell surface expression of CCR5 on CD4+ T-cells is highly
variable between individuals,13 and, in vitro, this variability has
been shown to affect HIV Infectivity in cell lines,14 macrophages,15
and lymphocytes.16 Initially, Platt et al.14 identiﬁed a threshold of
10 000 CCR5 molecules per CD4+ cell as a minimum requirement
for HIV infection. Levels below this threshold resulted in markedly
reduced infectability, but recent studies17 have shown that speciﬁc
viral isolates use lower levels of CCR5 more efﬁciently. Reynes et al.
demonstrated that CCR5 expression affects virus production and
viral load, and individuals with a low viral load have CCR5 densities
below the threshold value.18
The aim of this study was to analyze individuals identiﬁed by
ﬂow cytometry with a low CCR5 density for variations in the CCR5
gene. A number of mutations that are known to affect CCR5 density
were found in the individuals analyzed, and included the D32
mutation present in 11 Caucasian individuals in a heterozygous
state and in a single Caucasian male in a homozygous state
(Table 3). The latter did not express CCR5 on the cell surface as
measured by ﬂow cytometry and is likely to be resistant to R5 HIV
infection. In previous studies, the D32 mutation was not found in
the black African population and this was conﬁrmed in the present
study. The mutation was, however, found at a signiﬁcantly higher
frequency when compared to previous South African studies,
which have reported D32 at a frequency of 0.07–0.09.8,10,12 The
higher allelic frequency found in this study is possibly the result of
the targeted approach in which individuals with reduced CCR5
density were sequenced. Genotypic assessment for D32 in
individuals with higher CCR5 density will determine whether this
is the case.
In the present study, the C101X mutation at nucleotide position
303 was found in a Caucasian individual who also presented with
the L55Q mutation (Table 3). This mutation has been described
previously in the South African population in a heterozygous state
and was restricted to the Caucasian group at an allelic frequency of
0.7.10 The mutation was originally discovered in a male homozy-
gous individual who remained uninfected despite continuous
exposure from an infected partner over a 10-year period.7 Analysis
of the mutant receptor showed lack of expression on the cell
surface, rendering the individual resistant to HIV infection. The
mutation affects an important cysteine residue involved in
disulﬁde linkage and results in premature termination of transla-
tion, with intracellular retention of the unfolded receptor.6
A mutation exclusive to the black and colored South African
populations, originally discovered by Peterson et al.,8 was also
found in the present study (Table 3). The mutation at nucleotide
position 673, known as R225X, was found in two black African
individuals in a heterozygous state. The mutation is found in the
Table 3
Open reading frame mutations detected in black Africans and Caucasians
DNA position Amino acid position Base change wt/ma Accession number/referenceb
105 P35 G/A 8
164 L55Q A/T rs1799863
180 R60S G/T rs1800940
303 C101X T/A rs1800560
554 D32 D32 rs333
582 Q194H G/T rs62625034
667 R223W C/T N
673 R225X C/T 8
817 N273H A/C N
1004 A335V C/T rs1800944
1016 Y339F A/T rs1800945
a For base change, ‘wt’ refers to wild-type allele and ‘m’ refers to mutant allele.
b Accession numbers as found in the SNP database (dbSNP), or reference number for the study in which the mutation was discovered. N refers to novel mutation detected in
this study.
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codon resulting in premature termination of translation. Folefoc
et al.9 created a mutant receptor construct containing this
mutation and found a complete absence of CCR5 expression at
the cell surface. Furthermore, this prevented HIV binding, and cells
containing the mutant receptor were resistant to R5 HIV infection.
Thus, the mutation in a homozygous state may provide resistance
to HIV.
A novel SNP was detected in the intron 1 region of the CCR5
gene at position 2273 (Table 2). The A/G SNP was found in two
black African heterozygous individuals. Studies have shown that
the region encompassing intron 1 is crucial for CCR5 gene
regulation and forms part of the Pd promoter.19,20 The region
consists of several protected areas containing important cis-acting
elements that affect CCR5 expression. The novel mutation detected
in the present study affects an ATG codon. According to Mummidi
et al.,21 these upstream ATG codons play important roles in
regulating CCR5 expression, as the upstream minicistrons that are
created regulate CCR5 protein output.
A novel mutation in the ORF of the CCR5 gene was found at
nucleotide position 667 and is a C/T SNP found in two heterozygous
black and two Caucasian South African individuals (Table 3). The
mutation affects the third ICL of the CCR5 protein where it results
in replacement of the basic arginine residue by the non-polar
tryptophan, with the arginine residue being highly conserved.6 A
mutation known as R223Q has been deﬁned previously in this
position and is known to signiﬁcantly affect HIV co-receptor
function, although it can still bind gp120.6 The novel mutation,
R223W, found in the present study, may have a similar effect.
A mutation at nucleotide position 817 corresponding to
position 273 in the protein was discovered in a single black South
African heterozygous individual (Table 3). The individual also
presented with the mutation R223W discussed above. The A/C SNP
results in an amino acid change of the polar residue asparagine to
the basic residue histidine (N273H). The mutation is located in the
third Extracellular loop (ECL) and its effect requires further
investigation.
The 50-untranslated region (UTR), introns, and 30UTR are
important in CCR5 gene regulation.21 Therefore, novel mutations
found within intron 2 (Table 2) may play a signiﬁcant role in CCR5
expression. In particular, the C/G SNP (10) found in a single black
South African heterozygous individual may be of considerable
importance, as this region plays a signiﬁcant role in the initiation of
translation.
In conclusion, sequence analysis detected a total of 75
mutations in the study cohort. This included 63 previously known
and 12 newly identiﬁed mutations. The mutations comprised 70
SNPs, four insertions, and the D32 mutation. Thirty-nine mutationswere exclusive to the black South African group, while 13 were
exclusive to the Caucasian South African group. There were no
mutations detected in the 54-bp region of exon 2b. The regions
with the highest number of mutations were the 30 ﬂanking region
and intron 2. Twelve mutations thus far only identiﬁed in the South
African population8,12 were identiﬁed in the present study.
The ORF contained nine previously identiﬁed mutations. Five of
these were found exclusively in black South African individuals,
while four were found in the Caucasian group only. There were no
mutations in the ORF that were present in both population groups.
The D32 mutation was found in 12 Caucasian individuals but was
not detected in the black South African group. With the exception
of a single homozygous male, all individuals who displayed the
D32 mutation were heterozygotes.
Twelve novel SNPs were identiﬁed in the present study
including two in the ORF. Seven mutations were exclusive to
the black South African group while three were exclusive to the
Caucasian group. Additional work is needed to determine the effect
of these novel mutations on CCR5 receptor function, including
ligand binding and HIV co-receptor activity. Although ﬂow
cytometry gives some indication of CCR5 surface expression,
expression may not be the consequence of a single mutation.
Consequently it is difﬁcult to correlate mutations detected in the
present study with the level of CCR5 expression at the cell surface.
However, our targeted approach, in which the majority of
individuals sequenced were low CCR5 expressers, has allowed
us to identify novel mutations in the CCR5 gene. As expected,
greater genetic diversity was present in black South Africans, with
39 of the mutations being exclusive to this group.
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